Psoriasis and human immunodeficiency virus infection*

https://doi.org/10.1016/0190-9622(92)70234-7Get rights and content

Abstract

Background: Psoriasis associated with human immunodeficiency virus (HIV) infection has been reported to be severe and perhaps associated with decreased survival.

Objective: Our purpose was to document the natural history, response to therapy, and effect of psoriasis and its treatment on survival in HIV-infected patients with psoriasis.

Methods: This was an observational cohort study of 50 persons with psoriasis and HIV infection followed up during a 2-year period.

Results: In one third of the patients the psoriasis appeared before 1978, the year when HIV seroconversion began in San Francisco (group I). In two thirds psoriasis developed after 1978 (group II). Group I had a lower mean age of onset (19 vs 36 years) and more commonly had a family history of psoriasis. Palmoplantar and inverse psoriasis were more common in group II. Severe psoriasis occurred in one fourth of this group (12 of 50 patients). The median survival in this group after diagnosis of acquired immunodeficiency syndrome (AIDS) was 19 months, which is comparable to the median survival for all AIDS patients diagnosed in San Francisco between 1984 and 1990.

Conclusion: Psoriasis in the setting of HIV disease may be mild, moderate, or severe. Standard therapies and zidovudine are effective in management. Survival does not seem to be adversely affected by the presence of psoriasis or its therapy.

References (18)

There are more references available in the full text version of this article.

Cited by (86)

  • Psoriasis and HIV infection, what do French dermatologists do?

    2019, Annales de Dermatologie et de Venereologie
  • Overview of Psoriasis

    2016, Therapy for Severe Psoriasis
  • Psoriasis

    2013, Emery and Rimoin's Principles and Practice of Medical Genetics
  • HIV-associated psoriasis: pathogenesis, clinical features, and management

    2010, The Lancet Infectious Diseases
    Citation Excerpt :

    Six (54%) patients had a good to excellent response and four (36%) had total clearance of psoriasis in one report in which the most effective dose was 75 mg/day.79 The use of acitretin has also resulted in rapid clearance of skin lesions in AIDS-associated reactive arthritis80 and is effective for pustular and erythrodermic HIV-associated psoriasis variants.32 Low dose acitretin (25 mg/day) when combined with ultraviolet A or B phototherapy (Re-PUVA or Re-UVB) results in rapid synergistic clearing of psoriasis.81

  • Dermatology of the Patient with HIV

    2010, Emergency Medicine Clinics of North America
    Citation Excerpt :

    As psoriasis can be the first presentation of HIV infection, HIV testing should be considered in a patient who has worsening of stable psoriasis or develops psoriasis de novo, especially in patients with risk factors for HIV infection.29,30 The severity of the presentation often correlates to the degree of immune suppression.31 Psoriasis vulgaris, classically appearing with thick white scale, may present with widespread involvement covering almost the entire body surface (Fig. 12).

  • HIV Infection and Rheumatic Diseases: The Changing Spectrum of Clinical Enigma

    2009, Rheumatic Disease Clinics of North America
    Citation Excerpt :

    Severe psoriasis vulgaris, pustular, or papulosquamous dermopathy with arthritis should alert one to look for HIV infection.34,35 Different patterns of psoriasis—vulgaris, inverse, guttate, palmoplantar, erythrodermic, and pustular—coexist with ReA.36,37 Cytotoxic CD8 cells predominate in HIV-positive ReA and PsA patients.32

View all citing articles on Scopus
*

Reprints not available.

1

From the Department of Dermatology, San Francisco General Hospital and University of California, San Francisco.

View full text